Anavex Completes Successful Preclinical Studies On Lead Alzheimer’s Drug Candidate

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Anavex Life Sciences Corp. (”ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer’s disease.

More: continued here









Leave a Reply